Mohs micrographic surgery as treatment option for non-basal cell or squamous cell carcinomas in the United States.
Conclusions: Studying demographics and tumor characteristics aid in understanding the utilization patterns of MMS. PMID: 31474170 [PubMed - as supplied by publisher]
Authors: deShazo R, Soltani-Arabshahi R, Krishnasamy S, Langley RG, Kalia S, Ståhle M, Langholff W, Goyal K, Fakharzadeh S, Galindo C, Srivastava B, Krueger G Abstract To the Editor: Patients with psoriasis are at increased risk of developing non melanoma skin cancer (NMSC), including squamous cell carcinoma (SCC) and basal cell carcinoma (BCC).1,2 The risk is especially elevated among those who previously received systemic treatment or phototherapy.2 Systemic treatments, including biologic therapies and methotrexate (MTX), are effective in managing immune-mediated diseases; however, they may increase suscept...
Accurate counting of nonmelanoma skin cancer in fair-skinned populations remains challenging due to high event rates. In the past, epidemiology data have often been limited to collection of the number of people affected, rather than the number of tumours. Venables and coauthors report on pathology data from across the U.K., which identified the first basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) each year in 2013 –2015 across the U.K. European age-standardized incidence rates of the first BCC and cSCC per patient per annum were 285 and 77 per 100 000 person-years, respectively.
Non-melanoma skin cancer (NMSC) is the most common cancer worldwide. Australia has the highest incidence of skin cancer in the world, exceeding 2000 per 100 000 person-years and it is increasing . In the USA, more than 3 million individuals are diagnosed with NMSC each year [2,3]. In the UK, during 2014–2016, about 147 000 new NMSC cases were diagnosed every year, more than 400 every day . Data show that between 1976 and 1984, the overall inc idence of basal cell carcinoma (BCC) increased by 145% and of cutaneous squamous cell carcinoma (cSCC) by 263%.
Transplant recipients have a significantly higher risk of developing non-melanoma skin cancers compared with the general population and squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) are the most common post-transplant malignancies. Although in the general population BCC outnumbers SCC 4:1, in transplant patients this ratio is reversed and SCC is more common, with a 65- to 250-fold increased incidence. As patients in immunosuppressed states are living longer after transplants, the incidence of skin cancer in this population continues to increase.
Cyclooxygenase-2 (COX-2) inhibitor has been associated with lower risk of several cancers, but epidemiological studies on skin cancer risk have been limited and inconclusive. COX-2 inhibitor use and risk of basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), and melanoma were evaluated in three prospective cohorts - the Nurses ’ Health Study (NHS, 2000-2012), NHS II (2001-2011), and the Health Professionals Follow-up Study (HPFS, 2002-2012). COX-2 inhibitor use and skin cancer incidence were assessed using biennial questionnaires, with cSCC and melanoma cases verified by pathological records.
Basosquamous carcinoma (BSC) is an aggressive skin neoplasm with features of both basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). While genetic and molecular drivers of BCC and SCC development have been extensively characterized, BSC pathogenesis remains unclear, in particular regarding the reprogramming of tumor keratinocytes towards basaloid or squamatized phenotypes. Here, by analogy to pathway switching previously observed in BCC escaping Hedgehog (Hh) inhibition, we demonstrate loss of Hh signaling and MAPK pathway activation associated with squamatization of BSC.
Conclusion: Commonly used thiazide and thiazide-like diuretics have photosensitizing potential, and some observational studies with important methodological limitations have linked their use to an increased risk of skin cancer. Well designed observational studies are needed to provide more solid evidence on this possible association.
Facial plast Surg 2019; 35: 368-376 DOI: 10.1055/s-0039-1695044The European Academy of Facial Plastic Surgery celebrates its 40th anniversary. We aimed to describe innovations in the diagnostics and treatment in head and neck skin cancer over the past 40 years as well as future perspectives. Landmark events, developments, and highlights over the past decades for basal cell carcinoma, cutaneous squamous cell carcinoma, and melanoma are discussed. [...] Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.Article in Thieme eJournals: Table of contents | Abstract | Full text
Skin cancers are relatively rare in patients with skin of color; however, they are an important public health concern because of disparities in patient outcomes. Gaps in skin cancer knowledge exist because of lack of large-scale studies involving people of color, and limitations in data collection methods and skin classification paradigms. Additional research is needed to address questions regarding risk and reasons for disparate skin cancer outcomes in these patients. We summarize the clinical and epidemiologic features for basal cell carcinoma, squamous cell carcinoma, and melanoma and touch on some of their unique featu...
AbstractPurpose of ReviewThe aim of this work is to review the role of advanced non-invasive imaging, such as reflectance confocal microscopy (RCM) and optical coherence tomography (OCT), in malignant melanomas and non-melanoma skin cancers (NMSCs) using data coming from the most recent literature, with a particular highlight on the results of the European experience.Recent FindingsExamination with RCM and OCT increases the accuracy of diagnosis. The most recent diagnostic clues for melanoma and NMSCs are revised. In addition, the application of these techniques in presurgical margin definition and in monitoring the effica...